Chronic Myeloid Leukemia: Second-Line Drug Evokes Faster Response, Fewer Side Effects, Pivotal Study Finds
Links shared publicly online about this topic.
- 1,112total visits
Chronic Myeloid Leukemia: Second-Line Drug Evokes Faster Response, Fewer Side Effects, Pivotal Study Finds
Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing fro
View full resource at medicalnewstoday.com
Tags: MRSA, Leukemia, Chronic Myelogenous Leukemia, Drug
Most Recently Shared on June 7, 2010 at 12:06 pm By:
Chronic Myeloid Leukemia: Second-Line Drug Evokes Faster Response, Fewer Side Effects, Pivotal Study Finds http://mnt.to/3Dz6 #mrsa
Also Shared By:
Advertisement
MNT Leukemia
@mnt_leukemia
Chronic Myeloid Leukemia: Second-Line Drug Evokes Faster Response, Fewer Side Effects, Pivotal Study Finds http://mnt.to/3Dz6
1 year ago...